DIA会员及用户请点击登录

登录

忘记用户 ID? or 忘记密码?

Not a Member?

创建账户并加入。

Menu 返回 Real-World-Evidence

Real World Evidence and Data Standards

This track showcases the most important initiatives in artificial intelligence, machine learning, real-world evidence, big data.

We will examine how and where these new technologies could and should be incorporated into drug development, approval, post authorisation studies and reimbursement processes, unlocking their potential and cost-efficiencies for the various stakeholders throughout the value chain.


Who is This Track Designed For?

Professionals involved in generating, using and evaluating real-world evidence, data specialists, observational study managers, informatics (bio and medical), data standards, data quality, clinical data management, clinical trial design, clinical operations, electronic health records and other data sources, submissions, health economics outcomes research and biostatistics. It will also benefit software developers, solution providers and device professionals..

Register Now

DIA Europe 2022 Brochure

The online program is now available. Explore the rich content we offer across 10 thought leadership tracks. 

View Searchable Programme

Topic Leaders

Alison Cave

Alison Cave, PhD

Chief Safety Officer

Medicines and Healthcare products Regulatory Agency (MHRA), United Kingdom

Patrice Verpillat

Patrice Verpillat, DrMed, MD, PhD, MPH

Head of Global Epidemiology

Merck Healthcare KGaA, Germany

DIA Europe 2022 Highlights

It will provide updates on key developments on the GCP Renovation (ICH E6, ICH E8), Clinical Trial Regulation, the Clinical Trial Information System, data submission, transparency, navigating ethical approval, study design in the digital age, innovative clinical trial designs (umbrella and platform trials, patient centricity), digital tools in development and other hot topics. It should be a must-attend for optimising development programmes and identifying cost savings through efficiency and innovation.


Explore All Tracks

获得信息并保持参与

不要错失任何机会——请加入我们的邮件列表,了解DIA的观点和事件。